Biotech Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Angiotech Pharmaceuticals, Inc.

Paclitaxel franchise broadened with license to Broncus Technologies

This agreement allows Broncus Technologies to incorporate Angiotech's pioneering Paclitaxel technology with their Exhale system to treat emphysema.

Emphysema is a chronic and progressive disease of lung tissue destruction, typically as a result of long-term cigarette smoking. It now represents the fourth leading cause of death in the United States. It is characterized by gradual destruction of lung tissue, which results in the loss of the lungs' natural elasticity, the collapse of small airways, and air trapping.

...

• View Other Issues of Biotech Week
  
• View Other NewsRx Publications